4-butyrolactone has been researched along with aphidicolin in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Anger, M; Carnwath, JW; Kues, WA; Motlik, J; Niemann, H; Paul, D | 1 |
Hirata, M; Ishizaka, Y; Minemoto, Y; Nakagama, H; Ohtsubo, M; Sasagawa, T; Shimura, M; Uchida, S; Yamashita, K | 1 |
2 other study(ies) available for 4-butyrolactone and aphidicolin
Article | Year |
---|---|
Cell cycle synchronization of porcine fetal fibroblasts: effects of serum deprivation and reversible cell cycle inhibitors.
Topics: 4-Butyrolactone; Animals; Aphidicolin; Bromodeoxyuridine; Cell Cycle; Cell Cycle Proteins; Cell Survival; Cells, Cultured; Culture Media, Serum-Free; DNA Fragmentation; Enzyme Inhibitors; Fetus; Fibroblasts; Flow Cytometry; In Situ Nick-End Labeling; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine; Transcription, Genetic | 2000 |
Loss of p53 induces M-phase retardation following G2 DNA damage checkpoint abrogation.
Topics: 4-Butyrolactone; Antineoplastic Agents; Aphidicolin; Blotting, Western; Caffeine; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cell Cycle; Cyclin B; Cyclin B1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Flow Cytometry; G2 Phase; Humans; Mitosis; Oncogene Proteins, Viral; Phenotype; Protein Kinases; Protein Serine-Threonine Kinases; Repressor Proteins; S Phase; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |